Abemaciclib,Trastuzumab,Fulvestrant
eli lilly,roche,Astrazeneca
[' fulv', 'abema', 'trastuzumab,(-trastuzumab deruxtecan),(-trastuzumab-deruxtecan)', 'abemaciclib', 'monarche', 'breast', 'monarcher']
#breastcancer results of monarcher found abemaciclib + trastuzumab +/- fulvestrant was associated w/numerically improved overall survival when compared to chemo + trastuzumab among pts w/hr+, her2+ advanced breast cancer. #esmo22 cc: 
Your official source for @DanaFarber Cancer Institute news | Research, science, and innovation | Media requests: media@dfci.harvard.edu or 617-632-4090